Chronic Idiopathic Constipation Clinical Trial
Official title:
A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
NCT number | NCT02481947 |
Other study ID # | BLI400-301 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | May 2015 |
Est. completion date | November 2015 |
Verified date | July 2020 |
Source | Braintree Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus lubiprostone in constipated adults.
Status | Completed |
Enrollment | 459 |
Est. completion date | November 2015 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female subjects at least 18 years of age - Constipated, defined by the following adapted ROME II definition: A. Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months: 1. Straining during > 25% of defecations 2. Lumpy or hard stools in > 25% of defecations 3. Sensation of incomplete evacuation for > 25% of defecations B. Loose stools are rarely present without the use of laxatives C. There are insufficient criteria for IBS - loose (mushy) or watery stool in the absence of laxative use for more than 25% of bowel movements Criteria A, B and C must be fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis. - Otherwise in good health, as determined by physical exam and medical history - If female, and of child-bearing potential, is using an acceptable form of birth control - Negative urine pregnancy test at screening, if applicable - In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study Exclusion Criteria: - Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon - Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1 - Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1 - Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of Visit 5 - Subjects who are pregnant or lactating, or intend to become pregnant during the study - Subjects of childbearing potential who refuse a pregnancy test - Subjects who are allergic to any study medication component - Subjects taking narcotic analgesics or other medications known to cause constipation - Subjects with clinically significant cardiac abnormalities identified at the Visit 1 ECG - Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures - Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days - Subjects with an active history of drug or alcohol abuse - Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1 - Subjects who withdraw consent at any time prior to completion of Visit 1 procedures - Subjects with known or suspected moderate to severe hepatic insufficiency (Child Pugh Classes B and C) |
Country | Name | City | State |
---|---|---|---|
United States | BLI Research Site 10 | Anaheim | California |
United States | BLI Research Site 12 | Artesia | California |
United States | BLI Research Site 7 | Atlanta | Georgia |
United States | BLI Research Site 20 | Austin | Texas |
United States | BLI Research Site 9 | Austin | Texas |
United States | BLI Research Site 26 | Brandon | Florida |
United States | BLI Research Site 4 | Brandon | Florida |
United States | BLI Research Site 42 | Carrollton | Texas |
United States | BLI Research Site 48 | Channelview | Texas |
United States | BLI Research Site 35 | Charlottesville | Virginia |
United States | BLI Research Site 22 | Chattanooga | Tennessee |
United States | BLI Research Site 16 | Chicago | Illinois |
United States | BLI Research Site 14 | Cincinnati | Ohio |
United States | BLI Research Site 44 | Clearwater | Florida |
United States | BLI Research Site 28 | Corona | California |
United States | BLI Research Site 46 | DeLand | Florida |
United States | BLI Research Site 32 | Hialeah | Florida |
United States | BLI Research Site 40 | Hialeah | Florida |
United States | BLI Research Site 29 | Knoxville | Tennessee |
United States | BLI Research Site 30 | La Mirada | California |
United States | BLI Research Site 13 | Laguna Hills | California |
United States | BLI Research Site 49 | Las Vegas | Nevada |
United States | BLI Research Site 45 | Memphis | Tennessee |
United States | BLI Research Site 34 | Miami | Florida |
United States | BLI Research Site 36 | Miami | Florida |
United States | BLI Research Site 5 | Miami | Florida |
United States | BLI Research Site 8 | Miami | Florida |
United States | BLI Research Site 17 | Miami Lakes | Florida |
United States | BLI Research Site 43 | Miami Springs | Florida |
United States | BLI Research Site 38 | Mobile | Alabama |
United States | BLI Research Site 6 | Monroe | Louisiana |
United States | BLI Research Site 19 | Nashville | Tennessee |
United States | BLI Research Site 27 | New York | New York |
United States | BLI Research Site 15 | Newport News | Virginia |
United States | BLI Research Site 41 | Orange | California |
United States | BLI Research Site 11 | Orlando | Florida |
United States | BLI Research Site 18 | Orlando | Florida |
United States | BLI Research Site 47 | Owensboro | Kentucky |
United States | BLI Research Site 37 | Palmetto Bay | Florida |
United States | BLI Research Site 2 | Plano | Texas |
United States | BLI Research Site 39 | Raleigh | North Carolina |
United States | BLI Research Site 33 | Richland | Washington |
United States | BLI Research Site 50 | Sacramento | California |
United States | BLI Research Site 24 | Saint Petersburg | Florida |
United States | BLI Research Site 23 | San Diego | California |
United States | BLI Research Site 25 | Snellville | Georgia |
United States | BLI Research Site 3 | Tampa | Florida |
United States | BLI Research Site 21 | Tucson | Arizona |
United States | BLI Research Site 31 | West Monroe | Louisiana |
United States | BLI Research Site 1 | West Palm Beach | Florida |
Lead Sponsor | Collaborator |
---|---|
Braintree Laboratories |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Spontaneous Bowel Movement (CSBM) Response | The primary endpoint is based on the number of subjects who are weekly responders for at least 9 out of 12 weeks, with at least 3 of these weeks occurring in the last 4 weeks of treatment. A weekly responder is a subject who has = 3 CSBMs and an increase from baseline of > 1 CSBM in that week. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02361749 -
Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation
|
Phase 4 | |
Terminated |
NCT02239510 -
Efficacy of Linaclotide to Senna for CIC
|
N/A | |
Completed |
NCT01895543 -
Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
|
Phase 3 | |
Completed |
NCT01460225 -
Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
|
Phase 4 | |
Completed |
NCT02291679 -
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
|
Phase 3 | |
Completed |
NCT01989234 -
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation
|
Phase 2 | |
Completed |
NCT01993875 -
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
|
Phase 3 | |
Completed |
NCT01674530 -
Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation
|
Phase 3 | |
Completed |
NCT01429987 -
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
|
Phase 2/Phase 3 | |
Completed |
NCT01982240 -
12-Week Study of Plecanatide for CIC (The CIC3 Study)
|
Phase 3 | |
Completed |
NCT02590432 -
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
|
Phase 4 | |
Completed |
NCT01372423 -
Evaluation of Clinical Equivalence Between Two Lubiprostone Products
|
Phase 3 | |
Completed |
NCT03054506 -
The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
|
N/A | |
Recruiting |
NCT04804267 -
Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation
|
Phase 3 | |
Completed |
NCT03879239 -
Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation
|
N/A | |
Completed |
NCT01053962 -
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
|
Phase 2 | |
Completed |
NCT03097861 -
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
|
Phase 3 | |
Completed |
NCT03551873 -
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
|
||
Completed |
NCT02819310 -
An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults
|
Phase 3 | |
Completed |
NCT02819297 -
BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
|
Phase 3 |